Novartis AG (NYSE:NVS ... which we'll talk about a bit more over the course of the call; Kisqali's FDA approval and CHMP ...

Novartis hopes Kisqali will give Pfizer’s Ibrance (palbociclib) blockbuster a run for its money in first line HR+/HER2+ metastatic breast cancer. Although Pfizer beat Novartis to market with ...

Good morning and good afternoon, and welcome to the Novartis Q3 2024 Results Release ... talk about a bit more over the course of the call; Kisqali's FDA approval and CHMP positive opinion in ...

Meanwhile, Novartis has gained two new FDA approvals in the US for its breast cancer drug Kisqali and Fabhalta which is used in the reduction of proteinuria in adults. Commenting on Q3 2024 ...

Swiss pharma giant Novartis AG NVS reported better-than-expected ... driven by the momentum in Entresto, Kesimpta, Kisqali, Cosentyx, Pluvicto and Leqvio. The top line beat the Zacks Consensus ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Novartis is scheduled to report results for ... KEY DRUGS: Early breast-cancer treatment Kisqali, immunology drug Cosentyx, neuroscience medicine Kesimpta and cardiovascular drug Entresto--the ...

Unlike its recent important expansion for Kisqali in early-stage breast cancer, this time around, Novartis didn’t use a priority review voucher for the PSMAfore application to accelerate the FDA ...

Also Read: European Medicines Agency’s Panel Supports Approval Of Novartis’ Kisqali In Patients With Early-Breast Cancer Novartis generated $6 billion in free cash flow for the third quarter ...

Revenue from cancer medicine Kisqali and closely watched prostate cancer drug Pluvicto also slightly exceeded expectations. Novartis is focused on growth after years of constant change ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well as the robust performances of Kesimpta and Kisqali. Novartis released its ...